Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

Mechanistic Insights From Sequential Combination Therapy With An SGLT2 Inhibitor and DPP-IV Inhibitor: Results From the CANARIS Trial using Canagliflozin and Teneligliptin.

Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Tanaka S, Shiba T.

Diabetes Obes Metab. 2018 Aug 26. doi: 10.1111/dom.13505. [Epub ahead of print]

PMID:
30146790
2.

Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and reno-protection in type 2 diabetic patients with diabetic kidney disease.

Kitada M, Ogura Y, Nitta K, Fujii M, Kanasaki K, Konishi K, Iida Y, Nakagawa A, Koya D.

J Diabetes Investig. 2018 Aug 23. doi: 10.1111/jdi.12917. [Epub ahead of print]

3.

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Li X, Huang X, Bai C, Qin D, Cao S, Mei Q, Ye Y, Wu J.

Front Pharmacol. 2018 May 4;9:449. doi: 10.3389/fphar.2018.00449. eCollection 2018. Review.

4.

Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.

Kadowaki T, Haneda M, Ito H, Sasaki K, Hiraide S, Matsukawa M, Ueno M.

Adv Ther. 2018 Jun;35(6):817-831. doi: 10.1007/s12325-018-0704-2. Epub 2018 May 17.

5.

Evaluation of Teneligliptin Effects on Transcriptional Activity of PPARγ in Cell-Based Assays.

Takenaka Y, Inoue I, Nakano T, Ikeda M, Kakinuma Y, Ikegami Y, Shimada A, Noda M.

J Nippon Med Sch. 2018;85(2):95-101. doi: 10.1272/jnms.2018_85-15.

6.

Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.

Haneda M, Kadowaki T, Ito H, Sasaki K, Hiraide S, Ishii M, Matsukawa M, Ueno M.

Diabetes Ther. 2018 Jun;9(3):1083-1097. doi: 10.1007/s13300-018-0416-2. Epub 2018 Apr 10.

7.

Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin.

Minezumi T, Takeda SI, Igarashi Y, Sato K, Murakami Y, Nagata D.

Clin Med Insights Case Rep. 2018 Mar 20;11:1179547618763358. doi: 10.1177/1179547618763358. eCollection 2018.

8.

Mechanistic study for the simultaneous determination of metformin and teneligliptin in human plasma using hydrophilic interaction liquid chromatography-MS/MS.

Shah PA, Shrivastav PS, Vanol PG, Sanyal M.

Bioanalysis. 2018 Apr 1;10(7):475-488. doi: 10.4155/bio-2018-0007. Epub 2018 Mar 21.

PMID:
29561645
10.

Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study.

Agarwal P, Jindal C, Sapakal V.

Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):41-46. doi: 10.4103/ijem.IJEM_97_16.

11.

Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions.

De Nigris V, Prattichizzo F, Mancuso E, Spiga R, Pujadas G, Ceriello A.

Oncotarget. 2017 Dec 1;9(10):8898-8910. doi: 10.18632/oncotarget.22849. eCollection 2018 Feb 6.

12.

Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies.

Kadowaki T, Sasaki K, Ishii M, Matsukawa M, Ushirogawa Y.

Diabetes Ther. 2018 Apr;9(2):623-636. doi: 10.1007/s13300-018-0372-x. Epub 2018 Feb 12.

13.

Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement.

Kage Y, Yamaguchi Y, Uchida T, Izumi K, Nishie W, Shimizu H, Ishii N, Hashimoto T, Aihara M.

J Dermatol. 2018 Jul;45(7):e205-e206. doi: 10.1111/1346-8138.14237. Epub 2018 Jan 30. No abstract available.

PMID:
29380425
14.

Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor.

Takahara Y, Tokunou T, Ichiki T.

J Atheroscler Thromb. 2018 Aug 1;25(8):698-708. doi: 10.5551/jat.42481. Epub 2018 Jan 10.

15.

Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.

Kadowaki T, Haneda M, Ito H, Ueno M, Matsukawa M, Yamakura T, Sasaki K, Kimura M, Iijima H.

Expert Opin Pharmacother. 2018 Feb;19(2):83-91. doi: 10.1080/14656566.2017.1420165. Epub 2018 Jan 19.

PMID:
29268035
16.

Teneligliptin Prevents Cardiomyocyte Hypertrophy, Fibrosis, and Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats.

Yamamoto M, Ishizu T, Seo Y, Suto Y, Sai S, Xu D, Murakoshi N, Kimura T, Kawakami Y, Aonuma K.

J Card Fail. 2018 Jan;24(1):53-60. doi: 10.1016/j.cardfail.2017.09.001. Epub 2017 Sep 6.

PMID:
28888840
17.

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.

Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Gouda M, Iijima H, Watanabe Y.

Diabetes Obes Metab. 2018 Feb;20(2):453-457. doi: 10.1111/dom.13079. Epub 2017 Sep 15.

18.

Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario.

Shah K.

J Clin Diagn Res. 2017 Jun;11(6):OC22-OC25. doi: 10.7860/JCDR/2017/27013.10003. Epub 2017 Jun 1.

19.

Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.

Kadowaki T, Kondo K, Sasaki N, Miyayama K, Yokota S, Terata R, Gouda M.

Expert Opin Pharmacother. 2017 Sep;18(13):1291-1300. doi: 10.1080/14656566.2017.1359259. Epub 2017 Aug 10.

PMID:
28741385
20.

Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.

Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Watanabe Y, Gouda M, Iijima H.

Diabetes Obes Metab. 2018 Jan;20(1):77-84. doi: 10.1111/dom.13038. Epub 2017 Jul 31.

Supplemental Content

Loading ...
Support Center